Cyclerion Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 23.520007 USD (At close: Sep 8, 2026) · Market cap 15.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Details
| Name | Cyclerion Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 1 |
| Founded | 2018 |
| Ceo | Regina Graul |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US23255M2044 |
| Cusip | 23255M204 |
| Cik | 0001755237 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Rhonda M. Chicko CPA | Chief Financial Officer |
Contact
| Address | 245 First Street, Riverview II, 18th Floor, Cambridge, Massachusetts 02142, United States |
| Phone | 857 327 8778 |
| Website | https://www.cyclerion.com |